$16.51
0.482.99%
At Close: -
$16.52
0.010.08%
After Hours: Jul 26, 4:01 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Immunome (NASDAQ:IMNM) Stock, Analyst Ratings, Price Targets, Forecasts
Immunome Inc has a consensus price target of $24.29 based on the ratings of 7 analysts. The high is $35 issued by Guggenheim on April 15, 2024. The low is $8 issued by Cantor Fitzgerald on March 20, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, JP Morgan, and Guggenheim on May 31, 2024, April 30, 2024, and April 15, 2024, respectively. With an average price target of $28.67 between Piper Sandler, JP Morgan, and Guggenheim, there's an implied 73.50% upside for Immunome Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
JP Morgan
Guggenheim
Wedbush
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Immunome
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/31/2024 | Buy Now | 63.41% | Piper Sandler | Biren Amin | → $27 | Initiates | → Overweight | Get Alert |
| 04/30/2024 | Buy Now | 45.26% | JP Morgan | Brian Cheng | → $24 | Initiates | → Overweight | Get Alert |
| 04/15/2024 | Buy Now | 111.83% | Guggenheim | Michael Schmidt | → $35 | Initiates | → Buy | Get Alert |
| 04/01/2024 | Buy Now | 99.73% | Wedbush | David Nierengarten | $27 → $33 | Maintains | Outperform | Get Alert |
| 01/23/2024 | Buy Now | 15% | Wedbush | David Nierengarten | $12 → $19 | Maintains | Outperform | Get Alert |
| 12/19/2023 | Buy Now | -27.37% | Wedbush | David Nierengarten | → $12 | Initiates | → Outperform | Get Alert |
| 03/20/2023 | Buy Now | -51.58% | Cantor Fitzgerald | Pete Stavropoulos | → $8 | Reiterates | → Overweight | Get Alert |
| 03/17/2023 | Buy Now | -51.58% | Chardan Capital | Matthew Barcus | $9 → $8 | Maintains | Buy | Get Alert |
| 10/29/2021 | Buy Now | 111.83% | Cantor Fitzgerald | Brian Cheng | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Immunome (IMNM) stock?
The latest price target for Immunome (NASDAQ:IMNM) was reported by Piper Sandler on May 31, 2024. The analyst firm set a price target for $27.00 expecting IMNM to rise to within 12 months (a possible 63.41% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunome (IMNM)?
The latest analyst rating for Immunome (NASDAQ:IMNM) was provided by Piper Sandler, and Immunome initiated their overweight rating.
When was the last upgrade for Immunome (IMNM)?
There is no last upgrade for Immunome
When was the last downgrade for Immunome (IMNM)?
There is no last downgrade for Immunome.
When is the next analyst rating going to be posted or updated for Immunome (IMNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunome, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunome was filed on May 31, 2024 so you should expect the next rating to be made available sometime around May 31, 2025.
Is the Analyst Rating Immunome (IMNM) correct?
While ratings are subjective and will change, the latest Immunome (IMNM) rating was a initiated with a price target of $0.00 to $27.00. The current price Immunome (IMNM) is trading at is $16.52, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.